Pfizer Inc. (PFE) Gross Margin: 69.35%
Is Pfizer Inc.’s gross margin high or low?
Pfizer Inc.'s gross margin of 69.35% is in line with its 5-year average of 63.06%, near the high end of its 5-year range (50.95%–71.74%).
The gross margin for Pfizer Inc. (PFE) is 69.35% as of Wednesday, June 10, 2026. It is above its 12-month average by 1.91% (68.05%).
PFE Gross Margin Chart
PFE Average Gross Margin Chart
PFE Current vs Average Gross Margin Chart
PFE Gross Margin Metrics
GROSS MARGIN
69.35%
GROSS MARGIN AVG TTM
68.05%
GROSS MARGIN AVG 3Y
62.23%
GROSS MARGIN AVG 5Y
63.06%
GROSS MARGIN AVG 10Y
66.43%
GROSS MARGIN AVG 15Y
68.19%
GROSS MARGIN AVG 20Y
70.43%
CURRENT VS TTM AVG
+1.91%
CURRENT VS 3Y AVG
+11.43%
CURRENT VS 5Y AVG
+9.98%
CURRENT VS 10Y AVG
+4.40%
CURRENT VS 15Y AVG
+1.70%
CURRENT VS 20Y AVG
-1.53%
PFE Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | — | 69.35% | 68.05% | 62.23% | 63.06% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 66.29% | 66.73% | 66.82% | 67.04% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 79.35% | 78.55% | 78.10% | 78.28% |
| Abbott Laboratories (ABT) | $154.66B | 56.38% | 53.17% | 51.86% | 51.92% |
| Danaher Corporation (DHR) | $130.25B | 60.68% | 60.22% | 59.98% | 59.48% |
| CVS Health Corporation (CVS) | $125.16B | 13.87% | 13.78% | 14.92% | 15.96% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 68.75% | 62.23% | 59.55% | 57.82% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 39.41% | 39.50% | 40.36% | 43.54% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 86.28% | 85.57% | 86.56% | 87.08% |
| Amgen Inc. (AMGN) | $183.75B | 71.46% | 66.16% | 69.53% | 71.51% |
Gross Margin Analysis
Gross Margin
69.3%
(Revenue - COGS) / Revenue
Pfizer Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Gross Margin FAQ
- What is the gross margin for Pfizer Inc. (PFE)?
- The gross margin for PFE stock is 69.35%.
- Is Pfizer Inc.'s gross margin high or low?
- Pfizer Inc.'s gross margin of 69.35% is in line with its 5-year average of 63.06%, near the high end of its 5-year range (50.95%–71.74%).
- What is the TTM average gross margin for Pfizer Inc. (PFE)?
- The TTM average gross margin for PFE stock is 68.05%.
- What is the 3Y average gross margin for Pfizer Inc. (PFE)?
- The 3Y average gross margin for PFE stock is 62.23%.
- What is the 5Y average gross margin for Pfizer Inc. (PFE)?
- The 5Y average gross margin for PFE stock is 63.06%.
- What is the 10Y average gross margin for Pfizer Inc. (PFE)?
- The 10Y average gross margin for PFE stock is 66.43%.
- What is the 15Y average gross margin for Pfizer Inc. (PFE)?
- The 15Y average gross margin for PFE stock is 68.19%.
- What is the 20Y average gross margin for Pfizer Inc. (PFE)?
- The 20Y average gross margin for PFE stock is 70.43%.
Pfizer Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 70.33% |
| 2024-12-31 | 65.77% |
| 2023-12-31 | 50.95% |
| 2022-12-31 | 61.89% |
| 2021-12-31 | 57.67% |
| 2020-12-31 | 71.74% |
| 2019-12-31 | 69.34% |
| 2018-12-31 | 70.16% |
| 2017-12-31 | 69.97% |
| 2016-12-31 | 69.80% |
| 2015-12-31 | 73.07% |
| 2014-12-31 | 73.17% |
| 2013-12-31 | 72.95% |
| 2012-12-31 | 73.21% |
| 2011-12-31 | 71.88% |
| 2010-12-31 | 69.11% |
| 2009-12-31 | 76.82% |
| 2008-12-31 | 79.22% |
| 2007-12-31 | 75.79% |
| 2006-12-31 | 78.27% |
| 2005-12-31 | 77.84% |
| 2004-12-31 | 79.23% |
| 2003-12-31 | 78.24% |
| 2002-12-31 | 87.51% |
| 2001-12-31 | 84.40% |
| 2000-12-31 | 86.28% |
| 1999-12-31 | 87.74% |
| 1998-12-31 | 88.15% |
| 1997-12-31 | 85.83% |
| 1996-12-31 | 84.56% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla